Author:
Piltonen Terhi,Morin-Papunen Laure,Koivunen Riitta,Perheentupa Antti,Ruokonen Aimo,Tapanainen Juha S.
Publisher
Oxford University Press (OUP)
Subject
Obstetrics and Gynecology,Rehabilitation,Reproductive Medicine
Reference39 articles.
1. Allard S, Adin P, Gouedard L, di Clemente N, Josso N, Orgebin-Crist MC, Picard JY and Xavier F (2000) Molecular mechanisms of hormone-mediated Mullerian duct regression: involvement of beta-catenin. Development127, 3349–3360.
2. Anttila L, Koskinen P, Kaihola HL, Erkkola R, Irjala K and Ruutiainen K (1992) Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries. Fertil Steril58, 697–702.
3. Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC, Themmen AP and Grootegoed JA (1995) Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology136, 4951–4962.
4. Bili H, Laven J, Imani B, Eijkemans MJ and Fauser BC (2001) Age-related differences in features associated with polycystic ovary syndrome in normogonadotrophic oligo-amenorrhoeic infertile women of reproductive years. Eur J Endocrinol145, 749–755.
5. Cook CL, Siow Y, Brenner AG and Fallat ME (2002) Relationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril77, 141–146.